DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactStocks

Nifty 500: Sai Life Sciences hits record high; Astral shares hit 52-wk low on Q2 result

CNBC TV18 1 hr ago·6 Nov 2026, 4:32 am

Sai Life Sciences has reached a new all-time high, signaling strong market confidence in the company. The stock's rally comes as investors digest the company's recent quarterly performance, which has likely exceeded expectations. This surge highlights the sector's resilience and the company's growing operational strength.

For investors, this move underscores the importance of monitoring quarterly results for biotechnology and pharma stocks. A record high can indicate that the market is pricing in future growth, but it also brings the risk of volatility. It is crucial to assess whether the current valuation reflects sustainable performance or temporary hype.

Moving forward, investors should keep an eye on the company's future guidance and expansion plans. Any updates on new drug pipelines or strategic partnerships could further drive the stock's momentum. Staying informed about broader market trends will also help in making well-rounded investment decisions.

Excerpt from CNBC TV18

Published On Nov 6, 2026 | 10:02 IST Last Updated On Nov 6, 2026 | 10:02 IST The sell-off in select industrial and building-material stocks weighed on the Nifty 500, with Thermax and Astral falling sharply after their Q2 results. Sai Life Sciences gained 9% to hit an all-time high, while Astral slumped over 12% to a…

Read the original at CNBC TV18

Affected stocks

Bullish1 stock

Sai Life Sciences

SAILIFE Bullish

₹1,594.50

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Sai Life Sciences (SAILIFE).
Category: Stocks.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Sai Life Sciences worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at CNBC TV18.